Avantor, Inc. (NYSE: AVTR ), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials In other recent news, Avantor Inc. has faced several adjustments in analyst ratings and price targets following its latest earnings report. Goldman Sachs downgraded Avantor's stock from 'Buy' to 'Neutral' and slashed its price target to $14.00, citing concerns over the Laboratory Solutions segment's growth potential. Bernstein also lowered its price target to $15.00, maintaining a Market Perform rating due to disappointing first-quarter results and increased market competition. RBC Capital reduced its price target to $20.00 but maintained an Outperform rating, expressing optimism about Avantor's long-term prospects despite current challenges.